Welcome to our dedicated page for GeneDx Holdings news (Ticker: WGS), a resource for investors and traders seeking the latest updates and insights on GeneDx Holdings stock.
GeneDx Holdings Corp. reports developments in genomic testing for rare disease diagnosis, with recurring updates on ExomeDx™ and GenomeDx™ testing, exome and genome test volumes, revenue growth, and full-year outlooks. The company uses GeneDx Infinity™, a rare disease genomic dataset, to support clinical interpretation, AI-enabled variant analysis, and biopharma discovery.
Company news also covers research publications and medical-meeting abstracts, health economics studies involving whole exome and whole genome sequencing, sponsored genetic testing programs for suspected rare diseases, and partnerships intended to expand access to genomic diagnosis. Updates frequently connect clinical data, sequencing technology, and rare disease patient identification with the company's precision-medicine operating model.
GeneDx Holdings Corp. (Nasdaq: WGS) announced plans for an underwritten public offering of its Class A common stock, with an expected total gross proceeds of approximately $150 million. The offering will include a 30-day option for the underwriter to purchase an additional 15% of the shares. Concurrently, GeneDx will offer shares to institutional investors affiliated with its board members. The proceeds from these offerings will primarily fund general corporate purposes such as working capital, debt repayment, and strategic investments. Jefferies is the book-running manager for the public offering.